LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218858 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Chinmay Maheshwari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Hauptthemen laut MEDLINE: Neoplasms, RNA, Long Noncoding. Die Arbeit nennt 139 Literaturangaben. Gefördert von: National Institute of General Medical Sciences, National Cancer Institute.
Abstract (Originalsprache)
Long non-coding RNAs (lncRNAs) have emerged as critical regulators of the cancer epitranscriptome, orchestrating post-transcriptional gene regulation through dynamic interactions with RNA-modifying enzymes and RNA-binding proteins. Acting as molecular guides, scaffolds, decoys, and organizational hubs, lncRNAs regulate the deposition, removal, and interpretation of epitranscriptomic marks, including N6-methyladenosine (m6A), 5-methylcytosine, pseudouridine, and adenosine-to-inosine editing. Through these interactions, lncRNAs influence RNA stability, splicing, translation, localization, and degradation, thereby shaping oncogenic programs that drive proliferation, metabolic reprogramming, stemness, epithelial-mesenchymal transition, metastasis, immune evasion, and therapeutic resistance. Conversely, epitranscriptomic modifications regulate lncRNA abundance, structure, localization, and function, establishing reciprocal regulatory circuits that sustain adaptive cancer phenotypes. This review examines the bidirectional interplay between lncRNAs and the epitranscriptomic machinery, highlights emerging principles of epigenome-epitranscriptome integration, feedback regulation, and spatial organization, and explores their implications for cancer progression and therapeutic response. Understanding these interconnected regulatory networks may facilitate the development of novel biomarkers and precision therapeutic strategies targeting lncRNA-epitranscriptome signaling axes in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- Nvidia Corporation, 2788 San Tomas Expressway, Santa Clara, CA, 95051, USA.
- Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
- Myongji Hospital, Goyang, Republic of Korea; Seoul National University, College of Medicine, Seoul, 151-921, Republic of Korea.
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; D…
Förderung
- National Institute of General Medical Sciences
- National Cancer Institute
Zitieren
APA
Maheshwari, C., Nadhan, R., Nath, K., Shreeshapuranik, S. K., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2026). LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218858
Vancouver
Maheshwari C, Nadhan R, Nath K, Shreeshapuranik SK, Isidoro C, Song YS, et al. LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218858
BibTeX
@article{Maheshwari2026,
author = {Maheshwari, Chinmay and Nadhan, Revathy and Nath, Karthik and Shreeshapuranik, Shrinidhi Kota and Isidoro, Ciro and Song, Yong Sang and Dhanasekaran, Danny N},
title = {LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218858}
}
EUVIMED